J Nephropathol. 2012;1(3): 123-125. doi: 10.5812/nephropathol.8106
PMID: 24475401        PMCID: PMC3886149

Editorial

Paraoxonase enzyme activity and dyslipidemia in chronic kidney disease patients


Cited by CrossRef: 8


1- Baradaran A. Commentary on: effect of vitamin D on insulin resistance and anthropometric parameters in type 2 diabetes; a randomized double-blind clinical trial. DARU. 2013;21(1):19 [Crossref]
2- Nasri H. Reply: Oxytocin ameliorates cisplatin-induced nephrotoxicity in Wistar rats. Annals of Saudi Medicine. 2013;33(5):510 [Crossref]
3- Nasri H. The protective effect of recombinant human erythropoietin against cisplatin-induced renal and hepatic dysfunctions in Wistar rats. Hum Exp Toxicol. 2014;33(10):1085 [Crossref]
4- Nematbakhsh M, Nasri H. Cisplatin nephrotoxicity may be sex related. Kidney International. 2013;83(6):1201 [Crossref]
5- Nasri H. C-Phycocyanin attenuates cisplatin-induced nephrotoxicity in mice. Renal Failure. 2013;35(7):1054 [Crossref]
6- Nasri H. Helicobacter pylori and Serum Magnesium Level in Hemodialysis Patients. Jundishapur J Microbiol. 2014;7(2) [Crossref]
7- Nasri R. Renoprotective effects of metformin. DARU. 2013;21(1):36 [Crossref]
8- Nasri H. Re Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes. Diabetes & Metabolism. 2013;39(4):375 [Crossref]
9- Mohammed C, Xie Y, Brewster P, Ghosh S, Dube P, Sarsour T, Kleinhenz A, Crawford E, Malhotra D, James R, Kalra P, Haller S, Kennedy D. Circulating Lactonase Activity but Not Protein Level of PON-1 Predicts Adverse Outcomes in Subjects with Chronic Kidney Disease. JCM. 2019;8(7):1034 [Crossref]